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Abstract
Background: The imidazoquinoline derivate imiquimod induces inflammatory responses and protection against
transplanted tumors when applied to the skin in combination with a cognate peptide epitope (transcutaneous
immunization, TCI). Here we investigated the role of regulatory T cells (Treg) and the suppressive cytokine IL-10 in restricting
TCI-induced cytotoxic T lymphocyte (CTL) responses.
Methodology/Principal Findings: TCI was performed with an ointment containing the TLR7 agonist imiquimod and a CTL
epitope was applied to the depilated back skin of C57BL/6 mice. Using specific antibodies and FoxP3-diphteria toxin
receptor transgenic (DEREG) mice, we interrogated inhibiting factors after TCI: by depleting FoxP3
+ regulatory T cells we
found that specific CTL-responses were greatly enhanced. Beyond this, in IL-10 deficient (IL-10
-/-) mice or after blocking of IL-
10 signalling with an IL-10 receptor specific antibody, the TCI induced CTL response is greatly enhanced indicating an
important role for this cytokine in TCI. However, by transfer of Treg in IL-10
-/- mice and the use of B cell deficient JHT
-/- mice,
we can exclude Treg and B cells as source of IL-10 in the setting of TCI.
Conclusion/Significance: We identify Treg and IL-10 as two important and independently acting suppressors of CTL-
responses induced by transcutaneous immunization. Advanced vaccination strategies inhibiting Treg function and IL-10
release may lead the development of effective vaccination protocols aiming at the induction of T cell responses suitable for
the prophylaxis or treatment of persistent infections or tumors.
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Introduction
The development of new vaccination methods to successfully
combat malignant and infectious diseases is a central aim of
present studies. In this context transcutaneous immunization (TCI)
approaches seem to be a promising strategy. Combining an easy-
to-use administration, by avoiding the use of needles and therefore
allow self-medication, and addressing the skin associated lymphoid
tissue (SALT) at the same time makes TCI an attractive
immunization strategy. For the induction of adaptive immune
responses the administered adjuvants has to be combined with an
antigen. Beside the well-studied adjuvants cholera toxin (CT) and
head-labile enterotoxin (LT) [1] the imidazoquinolin imiquimod
constitutes an adjuvant that passages through the epidermis
without the need of any pre-treatment of the skin.
Imiquimod is a synthetic TLR7 ligand [2] that induces a wide
range of inflammatory cytokines as IFN-a, TNF-a, IL-1a, IL-6
and IL-8 in immune cells like dendritic cells (DC), B cells,
keratinocytes and granulocytes [3–7]. In combination with a
cognate peptide epitope the application of imiquimod mediates a
strong primary immune response [8,9] leading to tumor protection
in a prophylactic model. In therapeutic tumor settings TCI merely
mediates a delay in tumor growth in transplanted EG.7 tumors
[10] as well as in B16 melanoma models [11,12]. An important
step in the development and improvement of TCI is an enhanced
understanding of the underlying mechanisms and limitations of
TCI with imiquimod. This might elicit the opportunity to increase
inflammatory factors or circumvent suppressing influences.
Concerning the activation of SALT after TCI with imiquimod
we and others have demonstrated that increased numbers of
CD11c
+ dermal DCs migrating out of the skin into the draining
lymph nodes where we could also detect an induction of IL-12
[13]. In terms of limiting factors regulatory T cells (Treg) may hold
a central position as their suppressive function has been shown to
be limiting in vaccinations against tumor antigens [14,15]. One
well-described route of suppression mediated by Treg is via the
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tory cytokines by DC and macrophages.
In our present work we explored the role of Treg and IL-10 in
our transcutaneous vaccination setting. Here we show a strong
influence of Treg and also of the suppressive cytokine IL-10 on the
induced immune response. The negative influence of Treg seems to
be independent of the decreasing effects of IL-10 as they are not
the IL-10 producers in this system. To narrow the source of IL-10
further down we investigated in the role of B cells. A substantial
participation of B cells in this vaccination setting, either as IL-10
producers in the case of regulatory B cells or as distributers of
inflammatory cytokines after imiquimod application, could be
excluded.
Results
Regulatory T cells suppress TCI-induced CTL responses
Regulatory T cells (Treg) play a central role in maintaining
peripheral tolerance by restricting immune responses. To under-
stand the underlying mechanisms and advance the vaccination
strategy we were interested in the influence of Treg in the described
immunization protocol. To this end, we immunized mice
(DEREG), transgenic for the diphtheria toxin receptor under the
FoxP3 promoter. By administration of diphtheria toxin (DT)
FoxP3
+ cells can be specifically ablated. FoxP3-sufficient and -
depleted mice were immunized with transcutaneous immunization
(Figure 1). To control for the efficacy of DT administration, we
performed FoxP3-stainings of blood samples at the day immuniza-
tionstarted(d0)andatthereadouttime point(d 7).Injection ofDT
led to a decreased population of CD4
+FoxP3
+ T cells (1.74%, +/-
0.58%) compared to immunized (6.82%, +/- 0.93%) or untreated
(5.24%, +/- 0.16%) wild type mice at d 0. Staining of CD4
+FoxP3
+
T cells at d 7 revealed an increased population in the immunized
groups being more prominent in the wild type mice (11.74%, +/-
1.46%) compared to the previously depleted DEREG (Figure 1B).
Concerning induced T cell response analysis of peptide specific
CD8
+ T cells showed increased numbers in FoxP3-depleted mice
(Figure 1C). Compared to wild type ablation of Treg led to an
increased lysis of target cells by cytotoxic T cells (Figure 1D).
To assess the impact of Treg depletion on TCI in a non-
transgenic model and further underline the suppressive capacity of
CD25
+ regulatory T cells, we immunized C57BL/6 wild type mice
after depletion of CD25
+ cells by injection of a specific mAb (clone
PC61). Staining of CD4
+FoxP3
+ Treg showed a decreased cell
population after treatment with anti-CD25 (4.00%, +/- 1.88%)
compared to untreated groups (8.56%, +/- 1.00% and 8.22%, +/-
0.06%) at d0 (Figure 2A). At the time of read out, anti-CD25-
treated mice showed a slightly decreased amount of CD4
+FoxP3
+
Treg (6.59%, +/- 2.78%) compared the untreated control (8.39%,
+/- 1.06%). The immunized wild type group again showed an
increased population of Treg (12.19%, +/- 2.19%). We determined
induction of CTL response by the percentage of peptide-specific T
cells as well as the IFNc-production of blood samples and an in vivo
cytotoxicity assay to address the lytic capacity of cytotoxic T cells.
In line with the previous results Treg depletion increased the
number of specific T cells (3.32%, +/- 0.63%) compared to TCI in
the non-depleted wild type (1.14%, +/- 0.30%) (Figure 2B). In
addition an enhanced in vivo cytotoxicity (Figure 2C), shown in a
decreased population of peptide-loaded target cells, could be
defined (anti-CD25/TCI 50%, +/- 17.22%; TCI 21.2%, +/-
5.52%). These results demonstrate a fundamental role of Treg
suppressing or restricting induced CTL responses after immuni-
zation at the time of CTL priming rather than in the effector
phase.
IL-10 suppresses immune responses after TCI
After demonstrating that Treg suppress TCI-induced CTL
responses, we were interested in underlying mechanisms, in
particular the contribution of IL-10 since in vivo studies show
that naturally occurring as well as induced Treg produce IL-10
to control immune responses [16]. To address the role of IL-10
in the context of TCI we first immunized IL-10 deficient mice
(Figure 3). 7 days after treatments we analyzed the frequency of
peptide specific CD8
+ T cells and the lytic activity. In the
absence of IL-10 we found a high frequency of specific T cells
after TCI. Consistent with this, the in vivo cytotoxicity assay
showed enhanced lytic efficiency compared to wild type
controls. To further support the participation of IL-10 in
suppression of TCI-induced immune responses using a non-
transgenic model, we treated wild type mice as described before
with or without prior application of a blocking IL-10-receptor
Ab. The results found were in line with those received from the
IL-10
-/- mice. Bypassing the IL-10 signalling pathway led to
increased numbers of peptide specific T cells (Figure 3C) as well
as to nearly complete lysis of transferred and peptide loaded
target cells (Figure 3D) and enhanced production of IFNc (data
not shown). These results show a substantial participation of the
suppressive cytokine IL-10 in diminishing induced CTL
responses. Defining the cellular source of IL-10 would
contribute to the further understanding and advancing of
vaccination protocols.
Suppression of TCI induced CTL-responses by Regulatory
T cells is not mediated by IL-10
The suppressive effects of regulatory T cells may be mediated
via the release of IL-10, which also contributes to the regulation of
induced CTL-response. To evaluate whether Treg themselves
function as the major IL-10 producers, we used IL-10
-/- mice and
adoptively transferred purified CD4
+CD25
+ or only CD4
+CD25
-
T cells from wild type mice before immunization. This leads to a
situation where only the transferred naturally occurring Treg or
CD4
+CD25
- induced Treg are able to produce and release IL-10.
To address whether a cooperation between Treg and conventional
CD25
- T cells is necessary to release suppressive capacities we
transferred splenocytes from wild type mice containing with all T
cell populations (i.e. CD4
+CD25
+ as well as CD4
+CD25
- T cell
populations) as control. As shown in Figure 4, neither transfer of
purified Treg nor transfer of CD4
+CD25
- T cells nor splenocytes as
a whole were able to suppress the enhanced CTL response in IL-
10
-/- mice to wild type level. This allows the conclusion that in this
vaccination model Treg mediate their suppressive capacity mainly
via other regulatory functions than IL-10. Alternative cell
populations acting as relevant IL-10 producers in this setting
need to be determined.
B cells are not responsible for the release of suppressive
IL-10
An alternative source of IL-10 may be a subpopulation of B
cells, called B10 [16]. Those cells are found in the spleens of naı ¨ve
mice and Yanaba and co-workers could show that they have the
capacity to influence T cell activation and inflammatory responses
via the release of IL-10 [17]. Also in cases of EAE [18], B cell-
produced IL-10 plays an important role in controlling severity of
EAE. To evaluate whether B cells are the main IL-10 source in our
immunization model we immunized JHT
-/- mice that are deficient
in B cells [19]. The lack of B cells leads to similar results compared
to wild type controls, as demonstrated by the percentage of peptide
specific T cells (Figure 5A) and by cytolytic activity (Figure 5B). To
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immunized mixed bone marrow chimeras that lack IL-10
production exclusively in B cells (JHT
-/-/IL-10
-/- RC57BL/6).
Control chimeras received bone marrow transplantation from wild
type and IL-10 deficient donors resulting in a complete repertoire
of cells able to produce IL-10 (Ly5.1/IL-10
-/- RC57BL/6). The
analysis of specific CD8
+ T cells reveals no participation of B cell-
derived IL-10 in this immunization strategy shown in equal
amounts of specific CD8
+ T cells in JHT
-/-/IL-10
-/- RC57BL/6
chimera as well as in the control chimera or wild type group
(Figure 5C).
This indicates that also B cells can be excluded as major players
of CTL responses induced by our TCI approach, either as
enhancers or as counter regulators by the release of IL-10.
Figure 1. FoxP3
+ regulatory T cells inhibit TCI-induced immune response. (A) Transcutaneous immunizations with imiquimod were
performed at days 0 and 1 with Aldara (50 mg together with 100 mg SIINFEKL peptide). Mice were additionally treated with diphtheria toxin (days -1,
1 and 3), anti-CD25 (day -5) or anti-IL-10R (day -2) as indicated. DEREG mice were depleted of FoxP3
+ regulatory T cells by intraperitoneal
administration of diphtheria toxin (1 mg). Percentages of CD4
+FoxP3
+ Treg were assessed at days 0 and 7 (B). Specific CD8
+ T cells (C) and cytolytic
activity (D) were quantified by flow cytometric analysis 7 days after immunization. The depicted results are cumulative from three independent
experiments with three mice per group. (*) Significant difference (p,0.05) by Mann-Whitney test.
doi:10.1371/journal.pone.0027911.g001
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To combat infectious or tumor diseases there is a great interest
in the development of new and effective vaccination strategies.
One promising candidate may be the transcutaneous immuniza-
tion with imiquimod. For this easy-to-use treatment various
information concerning the immune stimulatory capacity could
already be accumulated. These include amongst others the release
of cytokines and the induction of a potent primary immune
response when combined with a CTL-epitope [9], leading to
tumor protection in prophylactic models [10].
Targeting the skin as an immunological organ makes it difficult
to understand ongoing processes and to annihilate any emerging
problems because of the complex interactions of cells in the skin.
In terms of the transcutaneous immunization with imiquimod the
underlying cellular connections as well as the influencing cytokine-
profile is not known in detail. Beside the stimulatory capacity of
imiquimod on various cells especially in the skin also regulatory
mechanisms are induced. Regulatory CD4
+CD25
+ T cells can
elicit their suppressive capacity via the release of IL-10 [20,21]
what can be blocked by neutralizing anti-IL-10 Abs [21]. In our
present work we wanted to investigate the suppressive mechanisms
Figure 2. Reduction of regulatory T cell numbers results in enhanced immune responses. C57BL/6 mice were transcutaneously
immunized as described before. Were indicated mice received anti-CD25 (clone PC61, 500 mg i.p., day -5) for reduction of regulatory T cell numbers.
Percentages of CD4
+FoxP3
+ Treg were assessed at days 0 and 7 (A). Specific CD8
+ T cells (B) were quantified by H2-K
b-Tetramer staining (percentage of
CD8
+H2-K
b-SIINFEKL
+ cells). (C) Cytolytic activity was determined 8 hours after adoptive transfer of peptide-loaded splenocytes. Stated percentage
indicates specific lysis of target cells. A cumulative analysis of two independent experiments with three mice per group is shown.
doi:10.1371/journal.pone.0027911.g002
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regulatory T cells and IL-10. We demonstrate, that indeed Treg as
well as IL-10 have suppressive functions in this context. Since the
release of IL-10 by Treg is an important mechanism of suppression
in some models [22,23] we investigated the role of Treg derived IL-
10. As a result we can exclude that a relevant amount of IL-10
after TCI is produced by naturally occurring Treg or induced
CD4
+ CD25
– Treg since the transfer of IL-10 sufficient cells in the
knock out animals does not restore the wild type situation (Fig. 4).
Therefore concerning the mechanisms of Treg mediated suppres-
sion of TCI induced CTL activation, other modes of action are
obviously important: for example the transfer of cyclic adenosine
monophosphate (cAMP) via direct contact of Treg and DC [24,25],
GITR [26] or CTLA-4 [27] need to be investigated in the context
of TCI. In addition, TGF-b was found by several groups to be
involved in Treg-mediated suppression. However, depending on
the experimental approach (in vitro vs. in vivo) and the particular
animal model used the importance of TGF-b in Treg mediated
suppression is still being controversially discussed [28]. Neverthe-
less, it was recently shown that Treg-derived TGF-b1 suppressed
pathogenic T effector cells in a spontaneously occurring T cell-
mediated murine model for psoriasis [29]. Given the immense
importance of TGF-b in many biological and immunological
processes beyond Treg mediated suppression [30,31], it will remain
difficult to assess the true role of TGF-b in Treg without the
availability of cell specific knock out animals.
Figure 3. Prevention of IL-10 signalling enhances the induced immune response. IL-10
-/- and wild type mice were immunized as described
before. (A) Peptide specific T cells as well as (B) lysis of peptide loaded target cells were assessed. C57BL/6 mice were immunized with TCI. Where
indicated mice received an intraperitoneal injection of a blocking anti-IL-10-receptor antibody (aIL-10R, 250 mg, d-2). Shown are the results for (C) the
quantity of peptide specific T cells, and (D) in vivo lysis of transferred target cells. A cumulative analysis of three independent experiments with three
mice per group is shown. (*) Significant difference (p,0.05) by Mann-Whitney test.
doi:10.1371/journal.pone.0027911.g003
Figure 4. The suppressive capacity of regulatory T cells is not
mediated via IL-10. C57BL/6 and IL-10
-/--mice were immunized with
TCI as described before. Where indicated mice received purified
CD4
+CD25
+ or CD4
+CD25
- T cells or splenocytes (containing CD4
+CD25
+
and CD4
+CD25
-)(1610
6, d-2) from wild type donors by intravenous
injection. After 7 days the amount of H2-K
b-SIINFEKL
+CD8
+ T cells from
blood samples was assessed. A cumulative analysis of two independent
experiments with three mice per group is shown. (*) Significant
difference (p,0.05) by Mann-Whitney test.
doi:10.1371/journal.pone.0027911.g004
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types have to be taken in consideration, for example regulatory B
cells (B10) [18]. For this cell population, an important role in EAE
has been shown, but little is known about their general
embedment in other immune reactions. However a central
contribution of B10 cells in terms of regulating TCI-induced
immune response can be excluded.
As the suppressive capacity of IL-10 in the context of TCI is
axiomatic, further studies are required to identify the relevant
sources of IL-10. There are numerous cell types in the skin that are
well known IL-10 producers in principle including macrophages
[32], keratinocytes [33], mast cells [34] or the recently described
CD8
+ DC [32]. However, the individual role of these cells after
imiquimod treatment as relevant IL-10 producers is currently
unclear and needs further investigations.
In summary our data provide evidence that induced CTL
responses after TCI are subjected not only to conveying but also to
suppressing circumstances leading to a complex interplay of various
cell types and cytokines. Understanding the underlying mechanisms
in more detail would lead to further improvements of vaccination
protocols to combat tumors and persistent virus infections.
Materials and Methods
Ethics Statement
All animal work performed in this study was conducted
according to the national guidelines and was reviewed and
confirmed by an institutional review board / ethics committee
headed by the local animal welfare officer (Prof. Kempski) of the
University Medical Center (Mainz, Germany). The responsible
national authority finally approved the animal experiments, which
is the National Investigation Office Rheinland-Pfalz (Koblenz,
Germany). The Appoval ID assigned by this authority: AZ 23 177-
07/G08-1-023).
Mice
C57BL/6 mice at 6–8 weeks were obtained from the local
animal facility of the University of Mainz. DEREG mice (kindly
provided by T. Sparwasser) [35], IL-10
-/- mice [36] and JHT
-/-
mice (kindly provided by Ari Waisman) [19] are all on the
C57BL/6 background.
Transcutaneous immunization
Transcutaneous immunizations with imiquimod were described
previously [9]. Briefly, after complete removal of dorsal hair with
electric clippers 50 mg cream containing 5% imiquimod (Aldara)
together with OVA257–264 (100 mg in DMSO, kindly provided by
Dr Stevanovic, Department Immunology, Institute for Cell
Biology, University of Tu ¨bingen, Germany) were applied on the
skin of anesthetized mice on days 0 and 1. Where indicated anti-
IL-10-receptor antibody (250 mg day -2, i.p.) was additionally
applied. For regulatory T cell depletion DEREG mice received i.p.
injections of diphtheria toxin (1 mg) at days -1, 1 and 3 or C57BL/
6 mice were treated with. For adoptive transfer of regulatory T
Figure 5. B cells do not have an impact on TCI induced immune response. B cell deficient JHT
-/- and C57BL/6 wild type mice were
immunized with TCI. Specific CD8
+ T cells (A) and cytolytic activity (B) were quantified by flow cytometric analysis 7 days after immunization. To
assess the role of B cell-derived IL-10 C57BL/6 recipients received bone marrow transplantation of JHT
-/- (80 %) and IL-10
-/--mice (20 %). Control
C57BL/6 recipients were reconstituted with Ly5.1 (80 %) and IL-10
-/- (20 %) bone marrow. After complete reconstitution mice were immunized as
indicated and the amount of specific CD8
+ T cells were determined (C). A cumulative analysis of two independent experiments with three mice per
group is shown.
doi:10.1371/journal.pone.0027911.g005
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+CD25
+) or CD4
+ T cells (CD4
+CD25
-) cells were
purified from C57BL/6 mice as previously described [37]. For
generation of bone marrow chimeras C57BL/6 recipients were
lethally irradiated (9.5 Gy from Cs
137 source, OB58-BA, Buchler,
Braunschweig, Germany) and reconstituted by transfer of 5610
5
bone marrow cells from the indicated donor strains. The animals
were maintained under specific pathogen free conditions for 8
weeks before use.
Flow cytometric analyses and in vivo cytotoxicity assay
For flow cytometric analysis the following mAbs (all from
eBioscience, Frankfurt, Germany) have been used: APC-Cy7-
conjugated anti-CD8 (clone 53-6.7), APC-conjugated CD62L
(clone MEL-14), PE-conjugated anti-CD8 (53-6.7). Blood samples
were collected after tail vein incision. After a hypotonic lysis step
samples were incubated with mAbs on ice. For detection of
SIINFEKL-specific T cells samples were stained with H2-K
b
tetramer. Percentage of specific H2-K
b-SIINFEKL
+ cells were
determined among gated CD8
+ T cells. H2-K
b-SIINFEKL
+ CD4
-
CD8
- cells were regarded as unspecific stainings. In vivo cytolytic
activity was assessed by transfer of 2610
7 target cells labelled with
two different carboxyfluorescein diacetate succinimidyl ester-
concentrations (CFSE
high and CFSE
low). The CFSE
low population
has been additionally loaded with SIINFEKL-peptide. Splenocytes
of immunized and control mice were analysed by flow cytometry.
All analyses were performed with a LSRII Flow Cytometer and
FACSDiva software (BD Pharmingen, Hamburg, Germany).
Statistical analysis
Different groups were analyzed by Mann-Whitney test for
comparison between two groups as indicated. P,0.05 was
considered statistically significant.
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